Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*
Authors' conclusion
Our propensity score-matched, retrospective, observational study in patients hospitalized with severe COVID-19 showed no difference in mortality but significantly fewer adverse effects with baricitinib compared with tocilizumab.
Study context
- Population
- Adults with severe COVID-19, 11 acute care hospitals in Georgia, June–October 2021582 matched
- Participants
- 956 adults
- Exposure
- Baricitinib vs tocilizumab
- Baricitinibn = 291
- Tocilizumabn = 291reference
- Outcome
- In-hospital mortality
Methodological detailsobservational, propensity-score matched, multicentre
- Observational
- Propensity-score matched
- Multicentre
Main finding
As reported in the abstract
- No difference in mortality between the two groups
- Propensity score-matched
Observational data: associations, not effects.
Safety
Secondary infections · key secondary outcome: adverse effects
P < 0.01
Thrombotic events
P < 0.01
Acute liver injury
P < 0.01
Original publication
Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19*. Crit Care Med. Published 19 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →